You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

November 12, 2014

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Olysio indication expanded for combo use with Sovaldi in hepatitis C

FDA has approved simeprevir (Olysio, Janssen) in combination with sofosbuvir (Sovaldi, Gilead) as an oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis infection in adults. » Read about the newest addition to the hep C armamentarium

FDA approves Cyramza in combination with paclitaxel for advanced gastric cancer after prior chemotherapy

FDA has approved ramucirumab (Cyramza, Eli Lilly) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. » Read about this key drug in Eli Lilly’s oncology portfolio

Continuing Education

MTM essentials for weight management

This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to educate pharmacists about the prevalence, health consequences, and nonpharmacologic and pharmacologic treatment options for obesity, with a focus on the recommendations made in the 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exam and earn up to 2 CPE credits, click here to log in with the session code 14DT12-FKX42.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

FDA drug approvals-November 2014

New approvals for hep C, stomach cancer, and influenza. » Also read about fast-tracked drugs

 

RELATED ARTICLES

Bristol-Myers Squibb withdraws potential hep C combo therapy

Faster access to cancer drugs needed

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group